Safavi Mirmahalleh S R, Ramazanian M R, Moradi M, Ebrahimpour Azbari M. Analyzing and comparing the results of meta-synthesis and thematic analysis in identifying supply chain risks in the pharmaceutical industry. jhosp 2024; 22 (4) :384-406
URL:
http://jhosp.tums.ac.ir/article-1-6676-en.html
1- Ph.D. Candidate, Department of Industrial and Commercial Management, Faculty of Management and Economics, University of Guilan, Rasht, Iran.
2- Associate Prof. Department of Industrial and Commercial Management, Faculty of Management and Economics, University of Guilan, Rasht, Iran. *Corresponding Author Email: ramazanian@guilan.ac.ir
3- Associate Prof. Department of Industrial and Commercial Management, Faculty of Management and Economics, University of Guilan, Rasht, Iran.
Abstract: (305 Views)
Background and Purpose: Health status is undeniably one of the most critical indicators of social development and progress. Providing healthcare poses a significant challenge for human life, and managing the healthcare supply chain is of strategic importance. The aim of this research is to analyze and compare the results of meta-synthesis with thematic analysis in identifying the risks of the pharmaceutical industry's supply chain.
Methods: This research follows a qualitative approach, utilizing both meta-synthesis and thematic analysis to identify supply chain risks in the pharmaceutical industry. In the first step, a meta-synthesis and systematic review of related studies over the past twenty-three years were conducted, identifying one hundred articles, which were refined to twenty-six key articles for the research. In the next step, risks specific to Iran's pharmaceutical supply chain were identified through thematic analysis and semi-structured interviews with experts, using targeted sampling. Finally, the results from these two approaches were compared and analyzed.
Results: The meta-synthesis approach identified ten general supply chain risks in the global pharmaceutical industry. Similarly, the thematic analysis approach identified ten specific supply chain risks in Iran's pharmaceutical industry. Six risks were common to both approaches: low quality of raw materials, complexity and incompatibility of information systems, supply of foreign currency and financial payments, transportation and insurance issues, increase in the price of raw materials, and unavailability of medicines. These common risks are critical for both the global and Iranian pharmaceutical supply chains.
Conclusion: Stakeholders in Iran's pharmaceutical supply chain (including hospitals) should prioritize managing these six common risks to improve supply chain performance. Additionally, they should focus on the four unique risks identified through thematic analysis specific to Iran's pharmaceutical supply chain, applying appropriate control measures and activities.
Type of Study:
Original Article |
Subject:
سایر Received: 2024/03/16 | Accepted: 2024/06/29 | Published: 2024/08/9